Joint Clinical Trials Office

Search Clinical Trials

The physicians at Weill Cornell Medicine/NewYork-Presbyterian are dedicated to the pursuit of breakthrough research, and the safe and ethical management of clinical trials. Research study volunteers play a critical role in determining the effectiveness of new therapies and treatments. By participating in clinical trials, you may gain access to new research treatments before they are widely available. Healthy volunteers are also needed for many studies.

If you are interested in learning more about a specific study or area of research, please search below or use our A-Z Guide.

Safety of Immunosuppression in A Prospective Cohort of Inflammatory Bowel Disease Patients With a History of Cancer (SAPPHIRE)

This is a prospective, multi-center, observational study designed to determine if specific agents used for treatment of inflammatory bowel disease (IBD) are associated with the development of new or recurrent cancer in patients with IBD and a history of cancer.

 Commitments for enrollment include:

Incremental increase in VEGFR1+ and VEGFR2+ hemangiogenic cells predict relapse and tumor response in breast cancer (BC) patients.

TitleIncremental increase in VEGFR1+ and VEGFR2+ hemangiogenic cells predict relapse and tumor response in breast cancer (BC) patients.
Publication TypeConference Paper
Year of Publication2011
AuthorsJain S, Ward MM, O'Loughlin J, Boeck MA, Wiener N, Chuang E, Cigler T, Moore A, Donovan D, Lam C, Cobham MVallee, Schneider SE, Christos P, Baergen R, Lane ME, Mittal V, Raf, ii S, Vahdat LT

High-yield of CD34+ cells with bortezomib-basedmobilization regimen is associated with specific genomic expression patterns, decrease in SDF-1 plasma levels and up-regulation of CXCR4 in multiple myeloma (MM) patients.

TitleHigh-yield of CD34+ cells with bortezomib-basedmobilization regimen is associated with specific genomic expression patterns, decrease in SDF-1 plasma levels and up-regulation of CXCR4 in multiple myeloma (MM) patients.
Publication TypePresentation
Year of Publication2011
AuthorsWard M.M., Mark T., Manco M., Stern J., O'Loughlin J., Shore T.B., Pearse R.N., Jayabalan D., Skerrett D., Chen-King S., Lane M.E., Niesvizky R.

Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients.

TitleIncremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients.
Publication TypeJournal Article
Year of Publication2012

Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse.

TitleTetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse.
Publication TypeJournal Article
Year of Publication2013

Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.

TitleOvercoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.
Publication TypeJournal Article
Year of Publication2013
AuthorsNiesvizky R, Mark TM, Ward M, Jayabalan DS, Pearse RN, Manco M, Stern J, Christos PJ, Mathews L, Shore TB, Zafar F, Pekle K,Xiang Z, Ely S, Skerret D, Chen-Kiang S,Coleman M, Lane ME

Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach.

TitlePhase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach.
Publication TypeJournal Article
Year of Publication2014

Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patients.

TitleIxabepilone-induced mitochondria and sensory axon loss in breast cancer patients.
Publication TypeJournal Article
Year of Publication2014
AuthorsEbenezer GJ, Carlson K, Donovan D, Cobham M, Chuang E, Moore A, Cigler T, Ward M, Lane ME, Ramnarain A, Vahdat LT, Polydefkis M
JournalAnn Clin Transl Neurol
Volume1
Issue9

Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity.

TitlePro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity.
Publication TypeJournal Article
Year of Publication2015
AuthorsStanton SE, Ward MM, Christos P, Sanford R, Lam C, Cobham MV, Donovan D, Scheff RJ, Cigler T, Moore A, Vahdat LT, Lane ME, Chuang E
JournalBMC Cancer
Volume15
Pagination267